Brought to you by 
Syndax and Merck explore entinostat/Keytruda combination
06 Oct 2021
Executive Summary
Syndax Pharmaceuticals Inc. and Merck & Co. Inc. will conduct a Phase Ib/II trial to study the combination of Syndax’s HDAC inhibitor entinostat with Merck’s Keytruda (pembrolizumab) for advanced non-small cell lung cancer (NSCLC) or melanoma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Syndax and Merck explore entinostat/Keytruda combination
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice